Empowered Patient Podcast

Gabriele Brambilla is the CEO and Executive VP of AliraHealth and is looking for ways to humanize healthcare and involve patients in the entire drug development continuum. They deliver services to drug developers, medical device developers, and digital health solution providers.

Gabriele explains, "We call it democratization of life sciences research, the ability to use our technology to directly involve patients, in different phases of development of a drug or a device, in a very active partnership, not just a passive collection of data."

"So AliraHealth provides a continuum of services that starts from the very early phases of development of a drug or a device. And a drug would be for us the CMC, which is chemistry manufacturing control. It would go then to regulatory, so we help our clients to interact with the FDA, or EMA for Europe, and then register the drugs. And we run clinical trials for our clients and market access. Also the ability to deliver value and effectiveness in front of payers so that they can actually reimburse for the drug and give access to patients to the drug."

@AliraHealth #PatientCentric #DigitalHealth #DecentralizedClinicalTrials #Digitaltx #DrugDevelopment

AliraHealth.com

Listen to the podcast here

Gabriele Brambilla is the CEO and Executive VP of AliraHealth and is looking for ways to humanize healthcare and involve patients in the entire drug development continuum. They deliver services to drug developers, medical device developers, and digital health solution providers.

Gabriele explains, "We call it democratization of life sciences research, the ability to use our technology to directly involve patients, in different phases of development of a drug or a device, in a very active partnership, not just a passive collection of data."

"So AliraHealth provides a continuum of services that starts from the very early phases of development of a drug or a device. And a drug would be for us the CMC, which is chemistry manufacturing control. It would go then to regulatory, so we help our clients to interact with the FDA, or EMA for Europe, and then register the drugs. And we run clinical trials for our clients and market access. Also the ability to deliver value and effectiveness in front of payers so that they can actually reimburse for the drug and give access to patients to the drug."

@AliraHealth #PatientCentric #DigitalHealth #DecentralizedClinicalTrials #Digitaltx #DrugDevelopment

AliraHealth.com

Download the transcript here

Dr. Matt Wilson is the Founder and CEO of uMEd, bringing together healthcare providers and researchers to reach out to patients to participate in clinical trials. Using health data, uMed facilitates targeting good candidates for trials and helps the care provider educate patients about the value of participating in one or multiple clinical trials. In a very repeatable and scalable environment, uMed can match patients to specific study opportunities based on standardized queries.

Matt explains, "A lot of other organizations in the clinical study space that are looking at using health record data are using it in a very different way because they're generally focused on bringing together existing EMR data or claims data from lots of different healthcare providers and using that in of itself to identify trends and value for researchers. Whereas uMed is taking a different approach, saying, "Well, actually, their health record data is incredibly useful as a starting point to be able to identify potential study participants."

"We essentially have a common data infrastructure that sits across our network of healthcare providers, that's bound to the U.K. and now the U.S. as well, which will shortly be coming online. What we do in that network is each of these providers essentially say, "Yes, we want to be part of the uMed network." That allows us to be able to bring the data from those health records and normalize them across all of the different providers we're working with."

#uMed #PatientRecruitment #ClinicalTrials #MedicalResearch #ClinicalTrialRecruitment

uMed.io

Listen to the podcast here

Dr. Matt Wilson is the Founder and CEO of uMEd, bringing together healthcare providers and researchers to reach out to patients to participate in clinical trials. Using health data, uMed facilitates targeting good candidates for trials and helps the care provider educate patients about the value of participating in one or multiple clinical trials. In a very repeatable and scalable environment, uMed can match patients to specific study opportunities based on standardized queries.

Matt explains, "A lot of other organizations in the clinical study space that are looking at using health record data are using it in a very different way because they're generally focused on bringing together existing EMR data or claims data from lots of different healthcare providers and using that in of itself to identify trends and value for researchers. Whereas uMed is taking a different approach, saying, "Well, actually, their health record data is incredibly useful as a starting point to be able to identify potential study participants."

"We essentially have a common data infrastructure that sits across our network of healthcare providers, that's bound to the U.K. and now the U.S. as well, which will shortly be coming online. What we do in that network is each of these providers essentially say, "Yes, we want to be part of the uMed network." That allows us to be able to bring the data from those health records and normalize them across all of the different providers we're working with."

#uMed #PatientRecruitment #ClinicalTrials #MedicalResearch #ClinicalTrialRecruitment

uMed.io

Download the transcript here

Andrew Hall is the CEO of IMV Inc, which has developed a platform based on a lipid-in-oil technology that encapsulates the therapeutic. When injected subcutaneously, the drug remains in a specific location to reinvigorate the immune system to overcome the tumor surveillance that allows cancer to grow.

Andrew explains, "There is a checkered history in oncology drug development that is known as vaccines in oncology. For the longest period of time, they were so exciting and, unfortunately, so disappointing in the way they performed clinically. We believe with the technology that we've created at IMV, that we can make vaccines in oncology cool again. We are creating an ability to educate the immune system in a prolonged way, in a way that may present a historical retraction of why things failed before, or maybe it wasn't the targets that made them fail. Maybe it was the way in which the targets were delivered in a meaningful way."

"The initial clinical trials are around a lead product, maveropepimut-S. So the target there is Survivin. Survivin is a target that's been well understood in cancer biology for a long time because it is very typical for a lot of cancers. One of the challenges we have as a company is that we have a number of targets that we could go after in cancer, but we just don't have all of the money in the world. So the reason we've chosen the targets we have, and these are ovarian cancer, these are DBCL, so Diffuse Large B-cell lymphoma basically, and then bladder cancer and other solid cancer is, we know that these cancers are highly overexpressing the target of Survivin. And we know that Survivin, and it's kind of akin to its name, is required for the cancer cell to survive."

@IMV_inc #Immunotherapies #Immunotherapeutics #Cancer #Oncology #LipidinOilTechnology #Survivin #Halifax #NovaScotia

IMV-inc.com

Listen to the podcast here

Andrew Hall is the CEO of IMV Inc, which has developed a platform based on a lipid-in-oil technology that encapsulates the therapeutic. When injected subcutaneously, the drug remains in a specific location to reinvigorate the immune system to overcome the tumor surveillance that allows cancer to grow.

Andrew explains, "There is a checkered history in oncology drug development that is known as vaccines in oncology. For the longest period of time, they were so exciting and, unfortunately, so disappointing in the way they performed clinically. We believe with the technology that we've created at IMV, that we can make vaccines in oncology cool again. We are creating an ability to educate the immune system in a prolonged way, in a way that may present a historical retraction of why things failed before, or maybe it wasn't the targets that made them fail. Maybe it was the way in which the targets were delivered in a meaningful way."

"The initial clinical trials are around a lead product, maveropepimut-S. So the target there is Survivin. Survivin is a target that's been well understood in cancer biology for a long time because it is very typical for a lot of cancers. One of the challenges we have as a company is that we have a number of targets that we could go after in cancer, but we just don't have all of the money in the world. So the reason we've chosen the targets we have, and these are ovarian cancer, these are DBCL, so Diffuse Large B-cell lymphoma basically, and then bladder cancer and other solid cancer is, we know that these cancers are highly overexpressing the target of Survivin. And we know that Survivin, and it's kind of akin to its name, is required for the cancer cell to survive."

@IMV_inc #Immunotherapies #Immunotherapeutics #Cancer #Oncology #LipidinOilTechnology #Survivin #Halifax #NovaScotia

IMV-inc.com

Download the transcript here

Clark Lagemann is the CEO of Avidon Health which is helping organizations support employees as they recover from the disruption of COVID and adjust to the reconfiguration of the workplace. While many people are leaving their jobs for more income, Avidon is finding that employees are also seeking resources to address substance abuse, stress, and pain.

Clark explains, "The kinds of substances really expanded so significantly prior to COVID then post-COVID. Before COVID, we could talk about one in 10 adults who reported anxiety and depressive disorder. Since COVID and in 2020, that shot up to four in 10, so nearly 40% of American workers suffer from mental health issues."

"So things that they're going to rely on to help them get through this, alcohol, a substance, pills. Opioids are very common, then you can go into more illicit drugs. So, the most common things that we see in the workplace that we're doing for large organizations are alcohol addiction and typically some sort of prescribed medications."

"Substance use in the workplace causes absenteeism, lost productivity, and healthcare expenses. That's from the employer, so those are big expenses, soft and hard costs, but the employee is facing the same thing. They're missing out on work, and they have lifestyle side effects because they're now suffering and they're going through these challenges. So, the opportunity that we have really is to create awareness. We start talking about that personalization first, but then creating awareness, making sure employees know what's available to them, and doing it in a discrete setting."

@AvidonHealth #DigitalHealthCoaching #SubstanceUseSupport #CorporateWellness #CorporateWellBeing #SubstanceAbuse #Addiction

avidonhealth.com

Listen to the podcast here

Clark Lagemann is the CEO of Avidon Health which is helping organizations support employees as they recover from the disruption of COVID and adjust to the reconfiguration of the workplace. While many people are leaving their jobs for more income, Avidon is finding that employees are also seeking resources to address substance abuse, stress, and pain.

Clark explains, "The kinds of substances really expanded so significantly prior to COVID then post-COVID. Before COVID, we could talk about one in 10 adults who reported anxiety and depressive disorder. Since COVID and in 2020, that shot up to four in 10, so nearly 40% of American workers suffer from mental health issues."

"So things that they're going to rely on to help them get through this, alcohol, a substance, pills. Opioids are very common, then you can go into more illicit drugs. So, the most common things that we see in the workplace that we're doing for large organizations are alcohol addiction and typically some sort of prescribed medications."

"Substance use in the workplace causes absenteeism, lost productivity, and healthcare expenses. That's from the employer, so those are big expenses, soft and hard costs, but the employee is facing the same thing. They're missing out on work, and they have lifestyle side effects because they're now suffering and they're going through these challenges. So, the opportunity that we have really is to create awareness. We start talking about that personalization first, but then creating awareness, making sure employees know what's available to them, and doing it in a discrete setting."

@AvidonHealth #DigitalHealthCoaching #SubstanceUseSupport #CorporateWellness #CorporateWellBeing #SubstanceAbuse #Addiction

avidonhealth.com

Download the transcript here

Matthew Robinson is the Senior Vice President of R&D at Immunome, which is leveraging the information in memory B cells to target antibody therapeutics to kill tumor cells.

Matthew explains, "At Immunome, we believe that the antibodies that these B cells are making have an ability to see the different types of tumor antigens, or the specific epitopes on infectious disease. Our platform allows us to see that disease through the lens of the human B cell. We can interrogate what those antibodies are binding to, and we can use that information to help other patients."

"Right now, we have a couple of programs ongoing that are either in the clinic or moving towards the clinic. We have a program in infectious disease and COVID that is currently in phase 1b trials. It's a three-antibody cocktail. Those were isolated from patients who made a very robust antibody response to the disease and fought it off very effectively. Each of those antibodies was selected because they have different mechanisms of action."

"Our lead oncology program is against an under-studied or an under-recognized anti-inflammatory cytokine. It's a molecule that the immune system makes to essentially tell the rest of its other components to stop making an immune response. We isolated an antibody from a head-and-neck cancer patient that pointed us towards IL-38 as being a potential important target for head and neck cancer."

@Immunome #COVID19 #ImmunoOncology #MemoryBCells #AntibodyTherapeutics #AntibodyDrugConjugates #AutoimmuneDiseases #InfectiousDiseases

immunome.com

Listen to the podcast here

Matthew Robinson is the Senior Vice President of R&D at Immunome, which is leveraging the information in memory B cells to target antibody therapeutics to kill tumor cells.

Matthew explains, "At Immunome, we believe that the antibodies that these B cells are making have an ability to see the different types of tumor antigens, or the specific epitopes on infectious disease. Our platform allows us to see that disease through the lens of the human B cell. We can interrogate what those antibodies are binding to, and we can use that information to help other patients."

"Right now, we have a couple of programs ongoing that are either in the clinic or moving towards the clinic. We have a program in infectious disease and COVID that is currently in phase 1b trials. It's a three-antibody cocktail. Those were isolated from patients who made a very robust antibody response to the disease and fought it off very effectively. Each of those antibodies was selected because they have different mechanisms of action."

"Our lead oncology program is against an under-studied or an under-recognized anti-inflammatory cytokine. It's a molecule that the immune system makes to essentially tell the rest of its other components to stop making an immune response. We isolated an antibody from a head-and-neck cancer patient that pointed us towards IL-38 as being a potential important target for head and neck cancer."

@Immunome #COVID19 #ImmunoOncology #MemoryBCells #AntibodyTherapeutics #AntibodyDrugConjugates #AutoimmuneDiseases #InfectiousDiseases

immunome.com

Download the transcript here